Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
Patients with IBS-diarrhea with prior evidence of increased fecal 48 hour total bile acid and increased fasting serum 7alphaC4 who meet the following:
- BDQ- IBS symptoms: Positive by Rome lll criteria
- HAD: No restrictions on Hospital Anxiety/Depression score.
- Age: 18-65 years
- Gender: Men or women. Women of childbearing potential will have a negative pregnancy test before initiation of medication.
- Use of drugs or agents within the past 1 week or planned use in the subsequent 2 weeks during the study period (Birth control pill, estrogen replacement therapy, and thyroxine replacement are permissible exceptions):
- Agents that alter GI transit including opioids, narcotics, anticholinergics, tricyclic antidepressants, SNRI antidepressants.
- Analgesic drugs including opiates, NSAID, COX 2 inhibitors
- Intake of medication that could interfere with the interpretation of the study.
- Female subjects who are pregnant or breast-feeding. Females must be either surgically sterilized, postmenopausal (>12 months since last menses), or, if of childbearing potential, using reliable methods of contraception as determined by the physician.
- Abdominal surgery (except Appendectomy)
- Patients with known chronic liver disease or history of elevated AST/ALT 2.0 X upper limit of normal.
- BA synthesis and possible false positive or negative fecal bile acid or serum 7alphaC4 result. If there is no AST or ALT values in the medical record, the study physicians will determine if the tests need to be run.